Lucentis And Stelara Biosimilars Drive Formycon’s 2024 Financials
As The Firm Finalizes US And EU Commercialization Partners For Eylea Biosimilar
Despite reporting lower revenues in the first half of the year, Formycon continues to see value in its biosimilar projects, with a new candidate to be launched in the second half of 2024.
